Recs

0
Player Avatar TMFTycoon (37.88) Submitted: 3/20/2014 4:06:59 PM : Underperform Start Price: $63.48 INCY Score: +26.91

I think Incyte needs a secondary source of revenue besides its main drug, Jakafi, and in the meantime, shares have run up based on Jakafi's success.

Featured Broker Partners


Advertisement